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The D antigen is highly immunogenic and may cause allo-
immunization to occur after blood transfusion or pregnancy. 
Some RHD variant alleles express a D antigen that is missing one 
or more epitopes, thus putting a presumed D+ patient at risk for 
alloanti-D and hemolytic disease of the fetus and newborn. It is 
generally accepted that individuals who have a serologic weak 
D phenotype due to one of three alleles common in Caucasians, 
RHD*weak D types 1, 2, or 3, are not at risk for alloimmunization. 
In this study, blood samples from 46 obstetrics patients from a 
local health system were identified based on discrepant results 
between automated gel and manual tube testing (n = 20) or 
based on presentation with a serologic weak D phenotype 
(n = 26). RHD genotyping was performed using commercial and 
laboratory-developed tests. Of the 26 serologic weak D samples, 
18 (69.2%) were found to carry alleles RHD*weak D type 1, 2, 
or 3. The remaining eight samples (30.8%) were found to carry 
partial D alleles. Of the 20 samples submitted because of D 
typing discrepancy, 7 (35%) carried alleles RHD*weak D type 1, 
2, or 3, while 13 (65%) carried partial RHD alleles. This report 
summarizes the findings of one hospital system and its approach 
to integrating RHD genotyping into its assessment of risk of 
alloimmunization in obstetrics patients. It demonstrates that 
individuals with partial RHD alleles can present with serologic 
weak D phenotype, such that, without RHD genotyping, these 
individuals may not be identified as candidates for Rh immune 
globulin. The study also demonstrates that use of two methods 
(automated gel and tube testing) allows for identification of partial 
D cases that would otherwise be missed. Immunohematology 
2020;36:146–151.
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The D antigen is different from many other blood group 
antigens in that the antigen is not derived from one or a 
few amino acids, but rather from the presence of the entire 
protein; thus it contains many epitopes. Genetic variation 
within the RHD gene can alter expression of the antigen both 
qualitatively and quantitatively. A D protein that lacks one or 
more of the epitopes is referred to as a partial D antigen, and 
loss of epitopes is associated with risk of alloimmunization 
from exposure to D+ red blood cells (RBCs) during pregnancy 
or transfusion. The International Society of Blood Transfusion 
(ISBT) has reported over 90 different RHD alleles encoding 
partial D antigens. Other variations in the RHD gene 
significantly alter the number of antigenic sites expressed on 
the RBC membrane and are often referred to as weak D alleles.
There are many alleles for which the impact on epitopes 
has not been assessed or the risk of alloimmunization iden-
tified. The three most common RHD variants in Caucasian 
individuals are RHD*weak D types 1, 2, and 3. These three 
variants are estimated to be responsible for 85 percent of 
serologic weak D phenotypes in Caucasian individuals.1,2 
These alleles are uncommon in individuals of African descent, 
where a large number of variants have been identified. RHD 
genotyping of African American blood donors predicted 15.9 
percent have a partial D phenotype.3
Both partial D and weak D variants can give variable 
serologic results, depending on the reagent and serologic 
method used. There are several methods and reagents 
commercially available for D typing by serology. Several 
commercial antisera, both polyclonal and monoclonal, are 
used in standard agglutination reactions in tube. Variable 
reactivity with different sources of anti-D are noted because of 
the specific epitopes targeted by different reagents. There are 
also blends of monoclonal and polyclonal antisera to broaden 
the specificity of the reagent.
Tubeless systems for D typing use column agglutination 
technology, microplate solid-phase technology, and hemag-
glutination microplate technology. Some automated systems 
use a binary classification of samples as positive or negative 
whereas others are capable of grading samples that react 
weaker than expected.
Individuals who are D− are at risk for producing 
alloanti-D, as well as are individuals with partial RHD alleles, 
and even some with weak D phenotypes. An individual 
with RBCs that express a partial D phenotype would be at 
risk of alloanti-D directed at RBCs expressing the D antigen 
containing the missing epitope. Alloimmunization can occur 
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via blood transfusion or pregnancy. The significance of D in 
pregnant women and in women of childbearing potential is 
well appreciated in the obstetrics community.4,5 Maternal 
alloanti-D can cause mild to severe hemolytic disease of the 
fetus and newborn (HDFN).6–8 Importantly, some partial D 
phenotypes may present with a serologic weak D phenotype, a 
fact that causes confusion based on the terminology. Without 
the use of extensive serologic testing with antibody panels, 
standard serologic tests are unable to accurately deduce 
alloimmunization risk. Many blood banks do not resolve a 
serologic weak D phenotype in a patient, but instead treat them 
as D−. Many of these women may not be at risk, however, and 
can safely be treated as D+. Conversely, some women will test 
strongly D+ by automated methods but actually be at risk. 
RHD genotyping can predict risk of alloimmunization based 
on alleles. For this reason, use of RHD genotyping to determine 
D status is recommended for hospital blood banks caring for 
pregnant women and women of childbearing potential.1,9–11
RHD genotyping is available to blood banks and 
transfusion services, mostly via reference laboratories.1 
Currently, RHD genotyping may be performed using either 
laboratory-developed tests or commercially available research-
use-only reagents. Test methods in use include sequence-
specific primer–polymerase chain reaction (SSP-PCR), PCR-
restriction fragment-length polymorphism (RFLP), Sanger 
sequence analysis of genomic DNA or cDNA, solid support- or 
bead-based single nucleotide polymorphism arrays, and mass 
spectrometry-based genotyping.3 In the scenario of a pregnant 
woman who has produced alloanti-D, noninvasive prenatal 
testing for RHD can be used to predict the D status of the 
fetus.12,13 The clinical utility of RHD genotyping for predicting 
alloimmunization risk in the obstetrics population has been 
appreciated in Europe for many years.9,14,15
Particular RHD variant alleles are known to be more 
prevalent in different ethnic groups. The most common 
RHD variants in Caucasian individuals are RHD*weak D 
types 1, 2, and 3, where the sample is often negative in 
tube by direct agglutination, but positive by the indirect 
antiglobulin test (IAT).8 These alleles are not associated with 
alloimmunization.16 Individuals of African descent, however, 
are more likely to express a partial D phenotype, which can 
either present as strongly D+ or as serologic weak D+ and may 
unknowingly put a patient at risk for anti-D alloimmunization 
and, consequently, HDFN.3,17,18 D typing discrepancies or 
serologic weak D phenotypes can identify samples that need 
further testing to resolve (not all will be the same).
As per current American College of Obstetricians and 
Gynecology standards,19 pregnant women who present to 
the hospital blood bank as weak D+ are managed as D−.19 
These laboratory practices are designed to help protect 
pregnant women and women of childbearing potential from 
developing alloanti-D, thus reducing the risk of HDFN in 
future pregnancies. They are transfused with D− blood, and 
administration of Rh immune globulin (RhIG) is recom-
mended at appropriate times throughout the pregnancy and 
after delivery. Nevertheless, this approach is imperfect. Less 
than 100 percent specificity means that there is unnecessary 
administration of RhIG and unnecessary use of rare D− RBCs 
for transfusion. Less than 100 percent sensitivity means that 
there is a failure to administer RhIG or to provide D− RBCs 
when indicated. Although RHD genotyping was recently 
recommended to resolve ambiguous cases, many hospital 
laboratories do not have policies in place for if and when to use 
this method.
In 2015, an interorganizational group of transfusion 
medicine physicians and molecular immunohematology 
experts published their findings and recommendations after 
reviewing the literature. They determined that if women 
in the United States with serologic weak D phenotypes had 
RHD genotyping performed, about 13,000 of them would be 
RHD*weak D types 1, 2, or 3 and could be managed as D+.1 
This finding would eliminate unnecessary RhIG injections 
and the use of D− blood in these women. Based on this group’s 
assessment, a joint statement was issued by AABB that rec-
ommends that women with D typing discrepancies, variable 
D reactivity, direct agglutination results of 2+ or lower grade, 
or a serologic weak D phenotype be provided RHD genotyping 
for determination of weak or partial D status.1 Another study 
evaluated the cost-effectiveness of RHD genotyping as a test 
that can be performed once and the genotype result used to 
inform the management of multiple pregnancies over the 
course of a woman’s life.20
However, there is no guidance for blood banks as to how 
to implement this recommendation; therefore, there is no 
universal approach. A recent study showed one hospital’s 
approach by using several serologic criteria to identify can-
didates for RHD genotyping.11 This report illustrates the 
importance of RHD genotyping referred from a health care 
system comprising four separate hospitals and examines the 
findings of patient samples submitted for RHD genotyping 
due to serologic weak D phenotype or D typing discrepancy 
between automated gel and tube methods in the past 30 
months.
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Materials and Methods
Sample Selection
Blood samples from obstetrics patients received in the 
four hospital blood banks from July 2013 to January 2016 
were identified based on D typing discrepancies or weak D+ 
phenotypes. Of the 46 samples that met these criteria, 15 
were from African American individuals, 26 from Caucasian 
women, and 5 from individuals of unknown race.
Serologic Testing
Serologic testing was performed using Bio-Rad (Hercules, 
CA) (RH1) immunoglobulin (Ig)G and IgM monoclonal blend 
anti-D antiserum by standard tube agglutination methods 
and/or automated gel testing using the Ortho ProVue (Ortho 
Clinical Diagnostics, Raritan, NJ), which uses the ID MTS/
Gel cards for direct agglutination testing. Discrepancies were 
defined as samples that typed D+ (1+ to 4+) using ProVue 
automated gel testing while typing D− at immediate spin (IS) 
and D+ (1+ to 3+) at antihuman globulin (AHG) phase using 
tube method. Serologic weak D phenotype was defined as a 
sample that tested D− at IS and D+ by IAT.
RHD Genotyping
Peripheral blood samples collected in EDTA anticoagulant 
were submitted to the National Molecular Laboratory, 
American Red Cross for RHD genotyping. Genomic DNA 
was isolated from mononuclear cells using DSP DNA Blood 
Minikit (Qiagen, Carlsbad, CA). Genotyping was performed 
using RHD BeadChip (Immucor, Norcross, GA). In cases 
where variants were not identified using the array, RHD 
exon 8 RFLP for RHD c.1136 was performed and/or Sanger 
sequencing of RHD exons and exon/intron borders (GeneWiz, 
South Plainfield, NJ). Sequences were aligned with the 
reference sequence using Sequencher (GeneCodes, Ann Arbor, 
MI), in which variant bases were identified and used to predict 
amino acid changes and assign alleles using the ISBT RHD 
allele tables21 or RhesusBase 2.0.22
Results
RBC phenotyping for D was performed using standard 
tube method and direct agglutination testing by both IS and 
IAT, when indicated, for all 46 samples included in this study. 
The Ortho ProVue was used to test 20 of the samples. Serologic 
D typing using standard tube methods found 40 samples to be 
weak D+. Variable D typings were found in 20 samples when 
the first type was performed on the Ortho ProVue. These 
samples were found to be D+ on the Ortho ProVue, ranging 
in strength from 1+ to 4+ agglutination. The second D type 
was performed using standard tube testing with commercially 
available reagent antisera Bio-Rad anti-D (RH1) Blend 
antiserum. Of these samples, four were found to be 1+ to 2+ 
reactive at IS. These four samples all typed strongly positive 
(3+ to 4+) on the Ortho ProVue. The other 16 samples all typed 
as weak D, negative at IS and positive by IAT.
RHD Genotyping
A total of 43 samples were tested using RHD BeadChip, 
and 3 samples were tested using gel-based PCR and/or PCR-
RFLP to rule out common weak and partial D alleles, due to 
unavailability of these RHD BeadChips. Twenty of the samples 
that were tested using RHD BeadChips were also tested 
using PCR-RFLP for RHD c.1136C>T to rule out presence of 
RHD*DAU0. Of the 26 samples submitted because of serologic 
weak D phenotype, 8 (30.8%) were determined to be due to 
the presence of partial RHD alleles. The other 18 samples 
(69.2%) were determined to be RHD*weak D types 1, 2, or 
3 (Fig. 1A). Of the 20 samples submitted due to D typing 
discrepancies and variable reactivity, 13 (65%) were predicted 
to be partial D+. The other seven (35%) were determined to 
be RHD*weak D types 1, 2, or 3 (Fig. 1B). In all, 21 of 46 
samples (45.7%) were predicted to be partial D+, and 25 of the 
46 (54.3%) were RHD*weak D type 1 (n = 11), RHD*weak D 
type 2 (n = 11), and RHD*weak D type 3 (n = 3). Alleles in 
the RHD*DAR family represented the most common partial 
D identified (n = 9), presenting both as typing discrepancies 
(n = 4) and as serologic weak phenotypes (n = 5). RHD*weak 
partial D 4.0 allele was found in seven samples (five typing 
discrepancies and two serologic weak D). As shown in 
Table 1, of the 21 cases in which partial alleles were detected, 
RHD*DAR family was found in 9 cases (43%), RHD*weak 
partial D 4.0 was found in 7 cases (33%), RHD*DAU3 in 
1 (5%), RHD*DAU5 in 2 (9%), RHD*DCS1 in 1 (5%), and 
RHD*DNB in 1 (5%).
Discussion
Of the 20 samples submitted because of D typing 
discrepancies and variable reactivity, 13 samples (65% of 
discrepancy cases) were determined by RHD genotyping to 
be partial D+. These individuals were of Caucasian (n = 9), 
African American (n = 10), and unknown (n = 1) race. These 
patients would best be managed as D− and be administered 
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the RhIG injection. The other seven (35%) were determined to 
be RHD*weak D types 1, 2, or 3 and would not be predicted to 
be at risk for alloanti-D, and therefore would not require RhIG 
administration. The definition of a sample with a serologic 
weak D phenotype used in this study was one that tested D− 
at IS and weak D+ at AHG. However, the current definition 
also includes that the sample typing results were less than or 
equal to 2+ by initial testing in any method.1 It is likely that 
additional samples would have been identified as candidates 
for RHD genotyping if the current definition had been used.
Of the 26 samples submitted because of serologic weak D 
phenotype, 8 (30.7%) were determined to have partial RHD 
alleles associated with the production of allo anti-D. These 
individuals were of Caucasian (n = 17), African American 
(n = 5), and unknown (n = 4) race. The other 18 (69.3%) 
samples submitted because of serologic weak D phenotype were 
determined to be due to RHD*weak D types 1, 2, or 3. These 
individuals would not be predicted to be at risk for alloanti-D 
and, therefore, would not require RhIG administration.
Of all 46 samples, 20 samples (43.4%) were determined 
to have partial RHD alleles and these patients are at risk for 
alloanti-D production. The majority of these samples (45% of 
partial D+) were RHD*DAR family alleles, which are classified 
as partial RHD alleles.4 Interestingly, four of these samples 
were submitted as D typing discrepancies, and five presented 
as serologic weak D+ (Fig. 2). Heterogeneity of presentation 
was also seen with the RHD*weak D type 1, 2, and 3 samples, 
with 7 presenting as typing discrepancies and 18 as serologic 
weak D.
The cases compiled in this study highlight the fact that 
different testing methods, different monoclonal reagents, and 
subjective interpretations can yield discrepant results for D 
Fig. 1 (A) Samples submitted as weak D+. (B) Samples submitted 
for D typing discrepancy.
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Table 1. Summary of serology and molecular results for the 46 
















Positive 0/+ 4 RHD*DAR family Partial Yes
Positive 0/+ 5 RHD*weak partial D 
4.0
Partial Yes
Positive 0/+ 2 RHD*DAU5 Partial Yes
Positive 0/+ 1 RHD*DAU3 Partial Yes
Positive 0/+ 1 RHD*DCS1 Partial Yes
Positive 0/+ 4 RHD*weak D type 1 Weak No
Positive 0/+ 2 RHD*weak D type 2 Weak No
Positive 0/+ 1 RHD*weak D type 3 Weak No
NT 0/+ 5 RHD*DAR family Partial Yes
NT 0/+ 2 RHD*weak partial  
D 4.0
Partial Yes
NT 0/+ 1 RHD*DNB Partial Yes
NT 0/+ 7 RHD*weak D type 1 Weak No
NT 0/+ 9 RHD*weak D type 2 Weak No
NT 0/+ 2 RHD*weak D type 3 Weak No
RhIG = Rh immune globulin; IS = immediate spin; IAT = indirect antiglobulin 
test; NT = not tested.
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antigen typing. If used as the sole test method, automated 
gel testing would not have identified any of these samples as 
weak or partial D+. Based on the Ortho ProVue results alone, 
65 percent of these individuals would have been classified as 
D+ and no RhIG would have been administered when, in fact, 
they were partial D. Furthermore, this study demonstrates 
the advantage of using an alternate method such as tube 
testing to obtain the required second ABO/D type of a patient 
before transfusion and for purposes of determining RhIG 
prophylaxis. In more than half of the cases with discordant 
results between gel and tube testing, partial D alleles were 
identified such that these patients were identified as at risk for 
anti-D alloimmunization.
It is important for hospital blood bank physicians and 
obstetricians to be aware that not all samples with serologic 
weak D phenotype are due to weak D alleles; they can be due 
to a partial D phenotype. It is not widely known that partial D 
alleles can be associated with a serologic weak D phenotype, 
since generally they are thought to give strong reactivity using 
direct agglutination methods. However, it has been previously 
described that partial D antigens can present through D typing 
discrepancies.18
Also of note, patients presenting with a serologic weak D 
phenotype could be partial D+, especially if they are of African 
ancestry, where these alleles are common.3,10 In our experience, 
the most common partial RHD alleles found to be associated 
with weak reactivity and/or D typing discrepancies are the 
RHD*DAR family of alleles and the RHD*weak partial D 4.0 
allele, as this study also supports. These alleles are frequently 
identified in the African population.7 The RHD*DAR family 
of alleles is largely associated with production of alloanti-D. 
In the U.S. experience, the RHD*weak partial D 4.0 allele 
is also frequently identified in individuals with alloanti-D.23 
The risk of developing anti-D after transfusion or pregnancy 
in in-dividuals with these alleles is not known, but there are 
several reports of individuals with partial D phenotypes who 
have developed anti-D.14,17,24 Recently, the interorganizational 
group of transfusion medicine physicians and molecular 
immunohematology experts published a second report that 
recommends use of RHD genotyping for all serologic weak 
D phenotypes and included a discussion of the lack of clear 
alloimmunization risk in patients carrying RHD*weak D 4.0 
and RHD*weak D 4.1.25 As of yet, the ISBT Working Party 
on Red Cell Immunogenetics and Blood Group Terminology 
has not changed the classification of these alleles from their 
current status as encoding partial D antigens.21
Determination of an accurate D status is critical to 
determining the appropriate management of obstetrics 
patients. When patients are suspected of carrying a D variant, 
RHD genotyping can assign alleles and, from that information, 
provide information about risk of alloimmunization and 
candidacy for RhIG. Importantly, when patients are found 
to be RHD*weak D types 1, 2, or 3, the most common D 
variants in Caucasian individuals, they can be treated as 
D+, and avoid the unnecessary use of RhIG or D− RBCs for 
transfusion. The approach described in this report illustrates 
the heterogeneity of presentation of D variant antigens, the 
limitations of using the serologic weak phenotype alone to 
predict risk of alloimmunization, the utility of using two 
serologic methods to identify candidates for RHD genotyping, 
and the ability of RHD genotyping to resolve these cases and 
provide recommendations as it pertains to alloimmunization 
risk and candidacy for RhIG.
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